1.
Korman N, Papp K, Bagel J, Foley P, Morita A, Banerjee S, Colston E, Wang T, Throup J, Thaci D. Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Onset of Action in the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials. J of Skin [Internet]. 2021Nov.5 [cited 2022Dec.1];5(6):s39. Available from: https://www.jofskin.org/index.php/skin/article/view/1390